| Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 17963464 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Rapid reperfusion is the key treatment goal in patients with ST-segment elevation myocardial infarction (STEMI). The American College of Cardiology-American Heart Association (ACC-AHA) 2004 guidelines for the management of STEMI include recommendations for pharmacologic reperfusion with use of fibrinolytic agents. Fibrinolytic agents are the preferred pharmacologic class for the management of STEMI because of their ability to achieve reperfusion and to restore blood flow when administered within 12 hours of symptom onset. Four fibrinolytic agents are approved for the treatment of STEMI in the United States-streptokinase, alteplase, reteplase, and tenecteplase. Several clinical trials have demonstrated the beneficial effects of these therapies in reducing mortality rates in patients with suspected acute myocardial infarction. Alteplase is administered as an intravenous infusion. However, the relatively long half-lives of reteplase and tenecteplase enable bolus administration, which may be more convenient and less time consuming. Reteplase is administered as a double bolus, and dosing does not depend on the patient's weight; tenecteplase is administered as a single bolus, and dosing is weight based. Adherence to the ACC-AHA guidelines, as well as knowledge about the available fibrinolytic agents, is essential for physicians and pharmacists to make informed decisions regarding appropriate pharmacologic reperfusion strategies. |
| | |
Authors:
|
Daniel E Hilleman; James P Tsikouris; A Allen Seals; Jonathan D Marmur |
Related Documents
:
|
1721214 - Which factors determine the development of late potentials after first myocardial infar... 1098684 - Procainamide and phenytoin. comparative study of their antiarrhythmic effects at appare... 1968904 - Managing patients after myocardial infarction. 10406064 - What an interventional cardiologist should know about the pharmacological treatment of ... 17030684 - Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopa... 15919284 - Small "functional" size after mechanical aortic valve replacement: no risk in young to ... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Pharmacotherapy Volume: 27 ISSN: 0277-0008 ISO Abbreviation: Pharmacotherapy Publication Date: 2007 Nov |
Date Detail:
|
Created Date: 2007-10-29 Completed Date: 2007-12-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8111305 Medline TA: Pharmacotherapy Country: United States |
Other Details:
|
Languages: eng Pagination: 1558-70 Citation Subset: IM |
Affiliation:
|
Creighton University Cardiac Center, 2500 California Plaza, 3006 Webster Street, Omaha, NE 68131, USA. hilleman@creighton.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angioplasty, Transluminal, Percutaneous Coronary Clinical Trials as Topic Electrocardiography Emergency Medical Services Fibrin / drug effects, metabolism Fibrinolytic Agents / administration & dosage, pharmacokinetics, therapeutic use* Humans Myocardial Infarction / drug therapy*, mortality Myocardial Reperfusion / methods* Practice Guidelines as Topic |
| Chemical | |
Reg. No./Substance:
|
0/Fibrinolytic Agents; 9001-31-4/Fibrin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Smoking cessation: an overview of treatment options with a focus on varenicline.
Next Document: Antidepressant agents for the treatment of chronic pain and depression.